-
disodium 4-(2-chlorophenyl)-1-ethyl-6-methyl-5-[(propan-2-yloxy)carbonyl]-1,4-dihydropyridine-2,3-dicarboxylate hydrate
-
ChemBase ID:
153852
-
Molecular Formular:
C20H22ClNNa2O7
-
Molecular Mass:
469.82372
-
Monoisotopic Mass:
469.08801829
-
SMILES and InChIs
SMILES:
CCN1C(=C(C(C(=C1C(=O)[O-])C(=O)[O-])c1ccccc1Cl)C(=O)OC(C)C)C.O.[Na+].[Na+]
Canonical SMILES:
CCN1C(=C(C(=O)OC(C)C)C(C(=C1C(=O)[O-])C(=O)[O-])c1ccccc1Cl)C.O.[Na+].[Na+]
InChI:
InChI=1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1;/p-2
InChIKey:
QECLOEJXLYHXNF-UHFFFAOYSA-L
-
Cite this record
CBID:153852 http://www.chembase.cn/molecule-153852.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
disodium 4-(2-chlorophenyl)-1-ethyl-6-methyl-5-[(propan-2-yloxy)carbonyl]-1,4-dihydropyridine-2,3-dicarboxylate hydrate
|
|
|
|
|
IUPAC Traditional name
|
|
disodium 4-(2-chlorophenyl)-1-ethyl-5-(isopropoxycarbonyl)-6-methyl-4H-pyridine-2,3-dicarboxylate hydrate
|
|
|
|
|
Synonyms
|
|
4-(2-Chlorophenyl)-1-ethyl-1,4-dihydro-6-methyl-2,3,5-pyridinetricarboxylic acid 5-isopropyl ester disodium salt hydrate
|
|
BAY U6751 hydrate
|
|
|
|
|
CAS Number
|
|
|
MDL Number
|
|
|
PubChem SID
|
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
|
Acid pKa
|
3.819935
|
H Acceptors
|
6
|
H Donor
|
0
|
LogD (pH = 5.5)
|
0.3658084
|
LogD (pH = 7.4)
|
-3.0211155
|
Log P
|
3.03912
|
Molar Refractivity
|
127.2468 cm3
|
Polarizability
|
39.57013 Å3
|
Polar Surface Area
|
109.8 Å2
|
Rotatable Bonds
|
7
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
B3686
|
Caution Light sensitive. Store in amber vials. Biochem/physiol Actions BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output. |
PATENTS
PATENTS
PubChem Patent
Google Patent